Drug Discovery and Development

  • Home Drug Discovery and Development
  • Drug Discovery
  • Women in Pharma and Biotech
  • Oncology
  • Neurological Disease
  • Infectious Disease
  • Resources
    • Video features
    • Podcast
    • Webinars
  • Pharma 50
    • 2025 Pharma 50
    • 2024 Pharma 50
    • 2023 Pharma 50
    • 2022 Pharma 50
    • 2021 Pharma 50
  • Advertise
  • SUBSCRIBE

Colo. Governor Signs Controversial “Right to Try” Bill

By Drug Discovery Trends Editor | May 19, 2014

Colorado Gov. John Hickenlooper speaks at a news conference at the Capitol in Denver in this Wednesday, May 22, 2013 file photo. Hickenlooper Saturday afternoon May 17, 2014 signed Colorado's "Right to Try" bill, which was passed unanimously in the state Legislature. The "Right to Try" law allows terminally ill patients to obtain experimental drugs without getting federal approval. The bill doesn't require drug companies to provide any drug outside federal parameters, and there's no indication pharmaceutical companies will do so. (Source: AP Photo/Ed Andrieski, File)Nick Auden didn’t live to see the legislation, but the case of the Denver melanoma patient who died while seeking access to an experimental drug helped inspire a first-of-its kind law in Colorado.
 
The “Right to Try” law allows terminally ill patients to obtain experimental drugs without getting federal approval. It’s a proposal being advanced in several states by patient advocates who are frustrated by the years-long federal approval process for experimental drugs in the pipeline.
 
“There are experimental drugs out there that can and do save lives, and access needs to be expanded,” said Auden’s widow, Amy Auden of Lone Tree, Colo. Nick Auden died in November at age 41 after unsuccessfully lobbying two drug companies to use an experimental treatment outside of clinical trials. Auden had acknowledged there was no guarantee the drug would work.
 
Gov. John Hickenlooper on Saturday signed Colorado’s “Right to Try” bill, which was passed unanimously in the state Legislature.
 
Similar bills await governors’ signatures in Louisiana and Missouri, and Arizona voters will decide in November whether to set up a similar program in that state.
 
Supporters call it a ray of hope for dying patients trying to navigate the red tape of existing “compassionate use” guidelines for obtaining drugs outside clinical trials. The process requires federal approval.
 
“When you’re terminal and there’s a drug out there that might help you, it can seem that the obstacles to get that drug are insurmountable,” said state Sen. Irene Aguilar, a physician who co-sponsored Colorado’s bill.
 
Aguilar dubbed the measure the “Dallas Buyers Club” bill, after the movie about a determined AIDS patient who smuggled treatments from Mexico because they weren’t cleared for use in the United States.
 
But skeptics call “Right to Try” a feel-good campaign that won’t help dying patients.
 
The law doesn’t require drug companies to provide any drug outside federal parameters, and there’s no indication pharmaceutical companies will do so.
 
A 2003 lawsuit to force the U.S. Food and Drug Administration to expand the availability of investigational drugs failed. A federal judge disagreed that terminally ill people have a right to access to investigational medicine, and the U.S. Supreme Court declined to consider an appeal.
 
State-level approaches are an effort to circumvent the federal system, but critics say they won’t work.
 
“The FDA regulates drug development, and this doesn’t do anything to change that,” said Dr. David Gorski, a surgical oncologist and editor of the blog Science Based Medicine.
 
Gorski said a drug company “wouldn’t do anything to endanger a drug they’re potentially spending hundreds of millions of dollars to bring to market” through elaborate FDA trials.
 
Colorado’s bill got a careful no-comment from state doctors’ groups, hospitals and health insurers. The bill was amended to clarify that health care providers and insurers aren’t liable if a patient who uses a drug outside clinical trials gets sick or dies.
 
Supporters insist the states should push the envelope on clinical trials to speed up the work of federal drug regulators.
 
“It’s so basic, the right to fight for your own life,” said Darcy Olsen, president of the Phoenix-based Goldwater Institute, a conservative think tank that promotes “Right to Try” legislation in state legislatures.
 
Date; May 17, 2014
Source: Associated Press

Filed Under: Drug Discovery

 

Related Articles Read More >

Lokavant’s Spectrum v15 uses AI to cut trial-feasibility modeling from weeks to minutes
Prime time for peptide-based drug discovery 
Why smaller, simpler molecular glues are gaining attention in drug discovery
Glass vial, pipette and woman scientist in laboratory for medical study, research or experiment. Test tube, dropper and professional female person with chemical liquid for pharmaceutical innovation
Unlocking ‘bench-to-bedside’ discoveries requires better data sharing and collaboration
“ddd
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest news and trends happening now in the drug discovery and development industry.

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.
Drug Discovery and Development
  • MassDevice
  • DeviceTalks
  • Medtech100 Index
  • Medical Design Sourcing
  • Medical Design & Outsourcing
  • Medical Tubing + Extrusion
  • Subscribe to our E-Newsletter
  • Contact Us
  • About Us
  • R&D World
  • Drug Delivery Business News
  • Pharmaceutical Processing World

Copyright © 2025 WTWH Media LLC. All Rights Reserved. The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media
Privacy Policy | Advertising | About Us

Search Drug Discovery & Development

  • Home Drug Discovery and Development
  • Drug Discovery
  • Women in Pharma and Biotech
  • Oncology
  • Neurological Disease
  • Infectious Disease
  • Resources
    • Video features
    • Podcast
    • Webinars
  • Pharma 50
    • 2025 Pharma 50
    • 2024 Pharma 50
    • 2023 Pharma 50
    • 2022 Pharma 50
    • 2021 Pharma 50
  • Advertise
  • SUBSCRIBE